Last $123.85 USD
Change Today +0.79 / 0.64%
Volume 279.2K
PCYC On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:16 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

pharmacyclics inc (PCYC) Snapshot

Open
$122.61
Previous Close
$123.06
Day High
$126.22
Day Low
$122.47
52 Week High
02/21/14 - $154.89
52 Week Low
05/27/14 - $82.51
Market Cap
9.4B
Average Volume 10 Days
800.1K
EPS TTM
$1.11
Shares Outstanding
75.3M
EX-Date
--
P/E TM
112.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for PHARMACYCLICS INC (PCYC)

pharmacyclics inc (PCYC) Related Businessweek News

View More BusinessWeek News

pharmacyclics inc (PCYC) Details

Pharmacyclics, Inc., a biopharmaceutical company, designs, develops, and commercializes small-molecule drugs for the treatment of cancer and immune mediated diseases in the United States and internationally. The company offers IMBRUVICATM as a single agent for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. Its products candidate in clinical development includes IMBRUVICA BTK inhibitor, which is under multiple Phase I, II, III clinical trials for the treatment of naive and relapsed/refractory chronic lymphocytic leukemia, naive and relapsed/refractory diffuse large B-cell lymphoma, naive follicular lymphoma, relapsed/refractory mantle cell lymphoma, relapsed/refractory follicular lymphoma, relapsed/refractory multiple myeloma, Waldenstrom's macroglobulinemia, and relapsed/refractory marginal zone lymphoma. The company is also developing a BTK inhibitor lead optimization program, which is in Phase I clinical trials targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in multiple Phase I, II clinical trials for the treatment of cancer; and PCI-24781, a HDAC inhibitor abexinostat, which is in multiple Phase I, II clinical trials for the treatment of relapsed/refractory lymphomas and solid tumors. The company’s clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.

521 Employees
Last Reported Date: 08/8/14
Founded in 1991

pharmacyclics inc (PCYC) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: --
Chief Financial Officer and Principal Account...
Total Annual Compensation: $541.1K
Chief Operating Officer
Total Annual Compensation: $849.2K
Executive Vice President of Corporate Affairs
Total Annual Compensation: $126.2K
Chief of Quality & Technical Operations
Total Annual Compensation: $704.3K
Compensation as of Fiscal Year 2013.

pharmacyclics inc (PCYC) Key Developments

Pharmacyclics Appoints Shawn Cline Tomasello as Chief Commercial Officer

Pharmacyclics Inc. appointed Shawn Cline Tomasello as its Chief Commercial Officer. Prior to joining Celgene, Ms. Cline Tomasello was the National Director of Hematology for Rituxan(R) at Genentech.

Pharmacyclics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Pharmacyclics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's total revenue was $113,020,000 against $54,684,000 a year ago. Loss from operations was $37,204,000 against income of $12,031,000 a year ago. Loss before income taxes was $37,238,000 against income of $12,008,000 a year ago. Net loss was $37,057,000 or $0.49 basic and diluted per share against income of $12,351,000 or $0.16 diluted per share a year ago. Non-GAAP net loss was $19,712,000 or $0.26 basic and diluted per share against income of $19,212,000 or $0.49 diluted per share a year ago. For the six months, the company's total revenue was $232,397,000 against $57,530,000 a year ago. Loss from operations was $18,979,000 against $40,933,000 a year ago. Loss before income taxes was $18,975,000 against $40,877,000 a year ago. Net loss was $18,782,000 or $0.25 basic and diluted per share against $39,560,000 or $0.55 basic and diluted per share a year ago. Non-GAAP net income was $11,549,000 or $0.15 basic and diluted per share against loss of $9,121,000 or $0.13 basic and diluted per share a year ago.

Pharmacyclics Inc., Q2 2014 Earnings Call, Jul 31, 2014

Pharmacyclics Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PCYC:US $123.89 USD +0.83

PCYC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Celgene Corp $94.67 USD -0.0653
View Industry Companies
 

Industry Analysis

PCYC

Industry Average

Valuation PCYC Industry Range
Price/Earnings 100.0x
Price/Sales 21.3x
Price/Book 14.2x
Price/Cash Flow 105.3x
TEV/Sales 19.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit www.pharmacyclics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.